Eton Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Eton Pharmaceuticals, Inc. (ETON) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-19
- Eton Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $0.00.
- Eton Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$927.00K, a 899.14% decline from fiscal 2023.
- Eton Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $116.00K.
- Eton Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$3.08M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 8 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-19 | |
| 2024-12-31 | -$927.00K 10-K · filed 2026-03-19 | |
| 2023-12-31 | $116.00K 10-K · filed 2026-03-19 | |
| 2022-12-31 | -$3.08M 10-K · filed 2025-03-18 | |
| 2021-12-31 | -$645.00K 10-K · filed 2024-03-14 | |
| 2020-12-31 | -$8.17M 10-K · filed 2023-03-16 | |
| 2019-12-31 | -$5.38M 10-K · filed 2022-03-16 | |
| 2018-12-31 | -$2.58M 10-K · filed 2021-03-16 | |
| 2017-12-31 | -$1.78M 10-K · filed 2020-03-05 | -$1.78M 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |